Loading...

HRMY HARMONY BIOSCIENCES HOLDINGS INC Other Situations 8-K Filing

HRMN

HRMY

HARMONY BIOSCIENCES HOLDINGS INC

(HRMY)

2023 8-K

Financial Results Report

Trial Data Update

Financial Statements

Regulatory Compliance

Financial Statements

Board Appointment

Management Changes

Financial Results

Financial Results

Investor Day Announcement

Earnings Reports

Resignation and Name Change

Annual Meeting of Stockholders

Appointment of Chief Medica...

Financial Results Announcement

Sublicense Agreement

Financial Results Announcement

Earnings Report

Acquisition of Zynerba Phar...

Appointment of Director

Financial Results Announcement

Acquisition of Zynerba Phar...

Appointment of Officers

Generic Drug Filing

Credit Agreement Amendment

Merger Agreement

Financial Results Announcement

Entry into a Material Defin...

Financial Results Announcement

Appointment of CEO

Phase 3 INTUNE study on pit...

Financial Results Announcement

Management Changes

Management Changes

External Links:

Harmony Biosciences Holdings, Inc. has accelerated the timeline for completing its Phase 3 INTUNE study on pitolisant, with enrollment expected to be completed in Q2 2023 and topline data anticipated in Q4 2023.

AI Assistant

HARMONY BIOSCIENCES HOLDINGS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.